{"id":4418,"date":"2019-03-26T05:37:16","date_gmt":"2019-03-26T05:37:16","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&p=4418"},"modified":"2019-03-26T05:37:16","modified_gmt":"2019-03-26T05:37:16","slug":"%ce%ba%ce%bb%ce%b9%ce%bd%ce%b9%ce%ba%ce%ae-%ce%b4%ce%bf%ce%ba%ce%b9%ce%bc%ce%ae-%cf%86%ce%ac%cf%83%ce%b7%cf%82-2-%ce%bc%ce%b5-%cf%84%ce%bf-%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%ce%ba%ce%bf%ce%b2","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/el\/study_trials\/phase-2-trial-of-single-agent-cobimetinib-for-adults-with-systemic-histiocytosis\/","title":{"rendered":"\u0394\u03bf\u03ba\u03b9\u03bc\u03ae \u03a6\u03ac\u03c3\u03b7\u03c2 2 \u03c4\u03bf\u03c5 \u03ba\u03bf\u03b2\u03b9\u03bc\u03b5\u03c4\u03b9\u03bd\u03af\u03bc\u03c0 \u03c9\u03c2 \u03bc\u03bf\u03bd\u03bf\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2 \u03c3\u03b5 \u03b5\u03bd\u03ae\u03bb\u03b9\u03ba\u03b5\u03c2 \u03bc\u03b5 \u03c3\u03c5\u03c3\u03c4\u03b7\u03bc\u03b1\u03c4\u03b9\u03ba\u03ae \u03b9\u03c3\u03c4\u03b9\u03bf\u03ba\u03c5\u03c4\u03c4\u03ac\u03c1\u03c9\u03c3\u03b7"},"content":{"rendered":"

\u03a3\u03ba\u03bf\u03c0\u03cc\u03c2 \u03c4\u03b7\u03c2 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7\u03c2:<\/strong> \u03a0\u03c1\u03cc\u03ba\u03b5\u03b9\u03c4\u03b1\u03b9 \u03b3\u03b9\u03b1 \u03bc\u03b9\u03b1 \u03ba\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae \u03b5\u03bd\u03cc\u03c2 \u03bd\u03ad\u03bf\u03c5 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b1\u03c3\u03b8\u03b5\u03bd\u03ce\u03bd \u03bc\u03b5 \u03bd\u03cc\u03c3\u03bf Erdheim-Chester, \u03c4\u03c9\u03bd \u03bf\u03c0\u03bf\u03af\u03c9\u03bd \u03bf \u03b9\u03c3\u03c4\u03cc\u03c2 ECD (1) \u0394\u0395\u039d \u03c0\u03b1\u03c1\u03bf\u03c5\u03c3\u03b9\u03ac\u03b6\u03b5\u03b9 \u03c4\u03b7 \u03bc\u03b5\u03c4\u03ac\u03bb\u03bb\u03b1\u03be\u03b7 BRAF \u03ae (2) \u03c4\u03c9\u03bd \u03bf\u03c0\u03bf\u03af\u03c9\u03bd \u03bf \u03b9\u03c3\u03c4\u03cc\u03c2 \u03a0\u0391\u03a1\u039f\u03a5\u03a3\u0399\u0391\u0396\u0395\u0399 \u03c4\u03b7 \u03bc\u03b5\u03c4\u03ac\u03bb\u03bb\u03b1\u03be\u03b7 BRAF, \u03b1\u03bb\u03bb\u03ac \u03b4\u03b5\u03bd \u03ad\u03c7\u03bf\u03c5\u03bd \u03c0\u03c1\u03cc\u03c3\u03b2\u03b1\u03c3\u03b7 \u03c3\u03b5 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 BRAF \u03ae \u03ad\u03c7\u03bf\u03c5\u03bd \u03bb\u03ac\u03b2\u03b5\u03b9 \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 BRAF \u03ba\u03b1\u03b9 \u03b4\u03b5\u03bd \u03bc\u03c0\u03bf\u03c1\u03bf\u03cd\u03bd \u03bd\u03b1 \u03b1\u03bd\u03b5\u03c7\u03b8\u03bf\u03cd\u03bd \u03c4\u03bf \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf.<\/p>\n

\u03a7\u03bf\u03c1\u03b7\u03b3\u03cc\u03c2:<\/strong> Genentech \u03ba\u03b1\u03b9 \u039a\u03ad\u03bd\u03c4\u03c1\u03bf \u039a\u03b1\u03c1\u03ba\u03af\u03bd\u03bf\u03c5 Memorial Sloan Kettering<\/p>\n

\u03a3\u03c4\u03bf\u03b9\u03c7\u03b5\u03af\u03b1 \u03b5\u03c0\u03b9\u03ba\u03bf\u03b9\u03bd\u03c9\u03bd\u03af\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae:<\/strong> Eli L. Diamond, MD (212) 610-0243 \u03ae diamone1@mskcc.org<\/p>\n

\u0396\u03b7\u03c4\u03bf\u03cd\u03bc\u03b5\u03bd\u03b7 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c4\u03bf\u03c5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03bf\u03cd\u03c2:<\/strong> \u039a\u03ac\u03b8\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03ae\u03c2 \u03bc\u03b5 ECD \u03c0\u03bf\u03c5 \u03b5\u03af\u03bd\u03b1\u03b9 BRAF-\u03b1\u03c1\u03bd\u03b7\u03c4\u03b9\u03ba\u03cc\u03c2 \u03ae \u03c0\u03bf\u03c5 \u03b5\u03af\u03bd\u03b1\u03b9 BRAF-\u03b8\u03b5\u03c4\u03b9\u03ba\u03cc\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03b5\u03bd \u03bc\u03c0\u03bf\u03c1\u03b5\u03af \u03bd\u03b1 \u03bb\u03ac\u03b2\u03b5\u03b9 \u03ae \u03bd\u03b1 \u03b1\u03bd\u03b5\u03c7\u03b8\u03b5\u03af \u03b1\u03bd\u03b1\u03c3\u03c4\u03bf\u03bb\u03ad\u03b1 BRAF. \u039f\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03bf\u03c1\u03b9\u03c3\u03bc\u03ad\u03bd\u03b1 \u03bf\u03c6\u03b8\u03b1\u03bb\u03bc\u03bf\u03bb\u03bf\u03b3\u03b9\u03ba\u03ac \u03ae \u03ba\u03b1\u03c1\u03b4\u03b9\u03b1\u03ba\u03ac \u03c0\u03c1\u03bf\u03b2\u03bb\u03ae\u03bc\u03b1\u03c4\u03b1 \u03b5\u03bd\u03b4\u03ad\u03c7\u03b5\u03c4\u03b1\u03b9 \u03bd\u03b1 \u03bc\u03b7\u03bd \u03c0\u03bb\u03b7\u03c1\u03bf\u03cd\u03bd \u03c4\u03b1 \u03ba\u03c1\u03b9\u03c4\u03ae\u03c1\u03b9\u03b1 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae\u03c2 \u03ba\u03b1\u03b9 \u03b8\u03b1 \u03b1\u03c0\u03b1\u03b9\u03c4\u03b7\u03b8\u03b5\u03af \u03c0\u03c1\u03bf\u03bb\u03b7\u03c0\u03c4\u03b9\u03ba\u03cc\u03c2 \u03ad\u03bb\u03b5\u03b3\u03c7\u03bf\u03c2 (\u03bf \u03bf\u03c0\u03bf\u03af\u03bf\u03c2, \u03c9\u03c3\u03c4\u03cc\u03c3\u03bf, \u03bc\u03c0\u03bf\u03c1\u03b5\u03af \u03c3\u03c5\u03c7\u03bd\u03ac \u03bd\u03b1 \u03c0\u03c1\u03b1\u03b3\u03bc\u03b1\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03b8\u03b5\u03af \u03ba\u03bf\u03bd\u03c4\u03ac \u03c3\u03c4\u03bf\u03bd \u03c4\u03cc\u03c0\u03bf \u03b4\u03b9\u03b1\u03bc\u03bf\u03bd\u03ae\u03c2 \u03c4\u03bf\u03c5\u03c2). \u0397 \u03bc\u03b5\u03bb\u03ad\u03c4\u03b7 \u03b1\u03c0\u03b1\u03b9\u03c4\u03b5\u03af \u03bc\u03b7\u03bd\u03b9\u03b1\u03af\u03b5\u03c2 \u03b5\u03c0\u03b9\u03c3\u03ba\u03ad\u03c8\u03b5\u03b9\u03c2 \u03c3\u03c4\u03bf MSKCC, \u03b1\u03bd \u03ba\u03b1\u03b9 \u03bc\u03b5\u03c4\u03ac \u03b1\u03c0\u03cc \u03ad\u03bd\u03b1 \u03ad\u03c4\u03bf\u03c2 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae\u03c2 \u03c3\u03c4\u03b7 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae \u03b1\u03c5\u03c4\u03ad\u03c2 \u03bc\u03c0\u03bf\u03c1\u03bf\u03cd\u03bd \u03bd\u03b1 \u03b3\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03ba\u03ac\u03b8\u03b5 \u03b4\u03cd\u03bf \u03bc\u03ae\u03bd\u03b5\u03c2.<\/p>\n

\u0393\u03bd\u03c9\u03c3\u03c4\u03ac \u03ba\u03ad\u03bd\u03c4\u03c1\u03b1 \u03c0\u03bf\u03c5 \u03b4\u03ad\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 ECD \u03c3\u03c4\u03bf \u03c0\u03bb\u03b1\u03af\u03c3\u03b9\u03bf \u03c4\u03b7\u03c2 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ae\u03c2:<\/strong> Memorial Sloan-Kettering, \u039d\u03ad\u03b1 \u03a5\u03cc\u03c1\u03ba\u03b7, \u039d\u03ad\u03b1 \u03a5\u03cc\u03c1\u03ba\u03b7, \u0397\u03a0\u0391<\/p>\n

\u0391\u03bd\u03b1\u03b3\u03bd\u03c9\u03c1\u03b9\u03c3\u03c4\u03b9\u03ba\u03cc ClinicalTrials.gov:<\/strong> NCT02649972<\/p>","protected":false},"excerpt":{"rendered":"

Study Objective: This is a clinical trial of a new medication to treat patients with Erdheim-Chester disease whose ECD tissue (1) does NOT have the BRAF mutation or (2) whose […]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4418","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/el\/wp-json\/wp\/v2\/study_trials\/4418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/el\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/el\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/el\/wp-json\/wp\/v2\/media?parent=4418"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/el\/wp-json\/wp\/v2\/study_trials_cat?post=4418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}